MetaCap

Edesa Biotech (EDSA) vs Telomir Pharmaceuticals (TELO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Edesa Biotech (EDSA) has outperformed Telomir Pharmaceuticals (TELO) over the past year, gaining 17.6% versus a loss of 71.6%. Edesa Biotech is the larger company by market cap ($27.0 million vs $26.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDSA+17.65%TELO-71.56%
+1028%+452%-124%
Nov 21, 20251 yearNov 20, 2026
EDSA-58.59%TELO-92.72%
+282%+86%-111%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDSA versus TELO key metrics
MetricEDSATELO
Share price$2.00$0.364
Market cap$27.02M$26.82M
1-day change-8.05%-17.24%
YTD return+40.85%-72.63%
1-year return+17.65%-71.56%
5-year return-95.63%—
EPS (TTM)$-1.72$-0.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.19M$-10.41M
52-week high$20.32$1.58
52-week low$0.72$0.353
Distance from 52-week high-90.16%-76.96%
Analyst consensusnonenone
Avg. price target upside+716.50%+998.90%
Average volume1.45M126.14K
Shares outstanding13.51M73.68M
Employees17—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDSA has outperformed TELO by 89.2 percentage points over the past year.

About Edesa Biotech

EDSA stock →

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Telomir Pharmaceuticals

TELO stock →

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.

Health Care · Biotechnology: Pharmaceutical Preparations

EDSA vs TELO FAQ

Which is bigger, Edesa Biotech or Telomir Pharmaceuticals?

Edesa Biotech (EDSA) is larger, with a market capitalization of $27.02M compared with $26.82M for Telomir Pharmaceuticals (TELO).

Which stock has performed better over the past year, EDSA or TELO?

EDSA returned +17.65% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.

Are Edesa Biotech and Telomir Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons